OCEANIC-STROKE (Phase 3 program of the Oral faCtor Eleven A iNhibitor asundexIan as novel anti-thrombotiC –STROKE study).

A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of ischemic stroke in male and female participants aged 18 years and older after an acute non-cardioembolic ischemic stroke or high-risk TIA